Trade Mark Journal No.2026/013 27 March 2026
WO0000001898193 (40,42)
Office of origin: United States of America
Date of International Registration:17 December 2025
Date of designation in the UK:
17 December 2025
International priority date claimed: 17 November 2025
(United States of America)
(99501527)
- Class 40
- Custom manufacture of reformulated pharmaceuticals for easier patient delivery; custom manufacturing, processing, and treating the therapeutic molecules of others; biomanufacturing for others, namely, manufacturing therapeutic molecules of others using biological organisms in the manufacturing process; custom manufacture of reformulated pharmaceuticals and therapeutics.
- Class 42
- Research and development in the field of pharmaceuticals and drug delivery; scientific and medical research, namely, conducting clinical trials for others; scientific research and design and development, namely, product design and development in the field of excipients and formulations for use with therapeutic biologics; scientific research and design, namely product design and development in the field of therapeutic formulation development; consulting in the fields of product design and development in the field of therapeutic formulation and excipient development; chemical engineering in the nature of formulation and reformulation of therapeutic compositions; development of new technology for others in the field of biomaterials, biotechnology and nanotechnology.
Halozyme, Inc.
Representative: Morgan, Lewis & Bockius UK LLP, Condor House, 5-10 St. Paul's Churchyard London EC4M 8AL UNITED KINGDOM